Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
Vebicorvir plus NRTI bij virologisch onderdrukte patiënten met chronische HBV
nov 2022 | Hepatitis, Hepatologie